# Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Canonical URL: https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal-gene-therapy-program-in-rett-syndrome
Ticker: TSHA
Company: Taysha Gene Therapies
Source: Taysha Gene Therapies
Published: 2026-01-06 13:00 EST
Original Source URL: https://ir.tayshagtx.com
## Summary

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to 22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion of ≥3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3, aged 2 to 4 years) in

## Article Body
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to 22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion of ≥3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3, aged 2 to 4 years) in
## Recent Company News
- 2026-06-25 20:01 EST — [Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-multiple-presentations-highlighting-its-tsha-102-4055adda) — Source: Taysha Gene Therapies
- 2026-06-25 02:34 EST — [Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-pricing-of-public-offering-of-common-stock-and-p-2e78d875) — Source: Taysha Gene Therapies
- 2026-06-24 20:01 EST — [Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-proposed-public-offering-of-common-stock-and-pre-4e5395e4) — Source: Taysha Gene Therapies
- 2026-06-22 12:00 EST — [Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-completion-of-dosing-in-reveal-pivotal-trial-and-251737f9) — Source: Taysha Gene Therapies
- 2026-06-05 12:01 EST — [Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/TSHA/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635--0dbdf043) — Source: Taysha Gene Therapies
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)